Business Context and Reporting Period
This Form 8-K filing by Moderna, Inc. (MRNA) reports corporate governance changes effective December 9, 2019. The company is a Delaware corporation with principal executive offices in Cambridge, MA, and is classified as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation: Peter Barton Hutt resigned from the Board of Directors and the Product Development Committee effective December 9, 2019. The resignation was not due to any disagreement with the Company.
- Consulting Role: Beginning December 10, 2019, Mr. Hutt will provide consulting services to the Company, during which his outstanding stock options will continue to vest.
- Appointment: The Board appointed François Nader, M.D., to fill the vacancy on December 10, 2019. Dr. Nader serves as a Class I director until the 2022 annual meeting and was appointed to the Product Development Committee.
Guidance, Outlook, and Compensation
The filing contains no financial guidance, outlook, or management commentary regarding business operations. However, it details the compensatory arrangements for the new director:
- Initial Grant: An option to purchase 39,720 shares of common stock, vesting in full on the one-year anniversary of the grant date.
- Additional Grant: An option to purchase 17,889 shares of common stock, vesting in full on the date of the 2020 annual meeting of stockholders.
- Exercise Price: Both grants are at the closing market price per share on the date of grant.
Key Facts for Investor Verification
- Confirm the effective date of Peter Barton Hutt's resignation and the start of his consulting arrangement.
- Verify the vesting schedule and share counts for François Nader, M.D.'s stock option grants.
- Review Dr. Nader's extensive prior board experience, including roles at Acceleron Pharma, Prevail Therapeutics, and Alexion Pharmaceuticals.
- Note that the resignation of Mr. Hutt was explicitly stated as not resulting from any disagreement with the Company.
